1. Sanyal AJ. Technical review on non-alcoholic fatty liver disease. Gastroenterology. 2002; 123: 1705-1725. doi: 10.1053/gast.2002.36572
2. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population based study and its association with biochemical and anthropometric measures. Liver Int. 2006; 26: 856-863. doi: 10.1111/j.1478-3231.2006.01311.x
3. Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003; 37: 1202-1219. doi: 10.1053/jhep.2003.50193
4. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231. doi: 10.1056/NEJMra011775
5. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. Gastroenterology. 1995; 108: 1607.
doi: 10.1016/0016-5085(95)90724-6
6. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of non-alcoholic steatosis syndromes. Semin Liver Dis. 2001; 21: 17-26. Website. http://www.ncbi.nlm.nih.gov/pubmed/11296693. Accessed June 27,2016
7. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000; 132: 112-117. doi: 10.7326/0003-4819-132-2-200001180-00004
8. Bedogni G, Bellentani S. Fatty liver: How frequent is it and why? Ann Hepatol. 2004; 3: 63-65.
Website. http://www.medigraphic.com/pdfs/hepato/ah-2004/ah042d.pdf. Accessed June 27, 2016
9. Marchesini G, Bugianesi E, Forlani G, et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003; 37: 917-923. doi: 10.1053/jhep.2003.50161
10. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107: 450-455. doi: 10.1016/S0002-9343(99)00271-5
11. Del Gaudio A, Boschi L, Del Gaudio GA, Mastrangelo L, Munari D. Liver damage in obese patients. Obes Surg. 2002; 12:802-804.
doi: 10.1381/096089202320995592
12. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004; 19: 854-858.
doi: 10.1111/j.1440-1746.2004.03312.x
13. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, andnon-alcoholic fatty liver disease. J Clin Endocrinol Metab. 2005; 90: 1578-1582. doi: 10.1210/jc.2004-1024#sthash.TTXOh4G5.dpuf
14. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic, steatosis and insulin resistance: Does etiology make a difference? J Hepatol. 2006; 44: 190-196. doi: 10.1016/j.jhep.2005.06.018
15. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16: 421-427.Website. http://journals.lww.com/co-lipidology/Abstract/2005/08000/Non-alcoholic_fatty_liver_disease_and_the_metabolic.6.aspx. Accessed June 27,2016
16. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as apredictor of non-alcoholic fatty liver disease. Ann Intern Med. 2005; 143: 722-728. doi: 10.7326/0003-4819-143-10-200511150-0009
17. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patientswith non-alcoholic fatty liver disease: The significance of dietary cholesterol. Scand J Gastroenterol. 2009; 44: 471-477. doi: 10.1080/00365520802588133
18. Musso G, Gambino R, De Michieli F, et al. Dietary habits andtheir relations to insulin resistance and postprandial lipemiain non-alcoholic steatohepatitis. Hepatology. 2003; 37: 909-916. doi: 10.1053/jhep.2003.50132
19. Assy N, Nasser G, Kamayse I, et al. Soft drink consumption linked withfatty liver in the absence of traditional risk factors. Can J Gastroenterol. 2008; 22: 811-816. doi: 10.1155/2008/810961
20. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab. 1998; 84: 137-144. doi: 10.1210/jcem.84.1.5371#sthash.1ZiBQiq2.dpuf
21. Lee JH, Rhee PL, Lee JK, et al. Role of hyperinsulinemia and glucose intolerance in the pathogenesis of non-alcoholic fatty liver in patients with normal body weight. Korean J Intern Med. 1998; 13: 10-14. doi: 10.3904/kjim.1998.13.1.10
22. Marchesini G, Brizi M, Bianchi G, et al. Non-alcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001; 50:1844-1850. doi: 10.2337/diabetes.50.8.1844
23. Pagano G, Pacini G, Musso G, et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolicsyndrome: Further evidence for an etiologic association. Hepatology. 2002; 35:367-372. doi: 10.1053/jhep.2002.30690
24. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35:373-379. doi: 10.1053/jhep.2002.30692
25. Cheung O, Sanyal AJ. Recent advances in non-alcoholic fatty liver disease. Curr Opin Gastroenterol. 2010; 26: 202-208.
doi: 10.1097/mog.0b013e328337b0c4
26. Koteish A, Diehl AM. Animal models of steatosis. Semin Liver Dis. 2001; 21: 89-104.
Website. http://www.ncbi.nlm.nih. gov/pubmed/11296700. Accessed June 27, 2016
27. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229. doi: 10.1016/0168-8278(91)90942-5
28. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Non-alcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology. 2004; 39: 1647-1654. doi: 10.1002/hep.20251
29. Eriksson S, Eriksson KF, Bondesson L. Non-alcoholic steatohepatitis in obesity: A reversible condition. Acta Med Scand. 1986; 220: 83-88.
doi: 10.1111/j.0954-6820.1986.tb02733.x
30. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998; 22: 222-226. Website. http://www.ncbi.nlm.nih.gov/pubmed/9539189. Accessed June 27, 2016
31. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99: 1408-1413. Website. http://www.ncbi.nlm.nih.gov/pubmed/2210247. Accessed June 27, 2016
32. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107. doi: 10.1016/S0168-8278(97)80287-5
33. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity. 2009; 17: 2162-2168. doi: 10.1038/oby.2009.126
34. Katan MB. Weight-loss diets for the prevention and treatment of obesity. N Engl J Med. 2009; 360: 923-925. doi: 10.1056/NEJMe0810291
35. Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN. Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res. 2003; 44: 2065-2072. doi: 10.1194/jlr.M300167-JLR200
36. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab. 2005; 90: 2804-2809. doi: 10.1210/jc.2004-983#sthash.f50f9cxy.dpuf
37. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemiain non-alcoholic steatohepatitis. Hepatology. 2003; 37: 909-916. doi: 10.1053/jhep.2003.50132
38. McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology. 2004; 40:386-393. doi: 10.1002/hep.20302
39. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin esistance in non-alcoholic fatty liver disease. J Biol Chem. 2004; 279: 32345-32353. doi: 10.1074/jbc.M313478200
40. Kim SP, Ellmerer M, Van Citters GW, Bergman RN. Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes. 2003; 52: 2453-2460. doi: 10.2337/diabetes.52.10.2453
41. Solga S, Alkhuraishe AR, Clark JM, et al. Dietary composition and non-alcoholic fatty liver disease. Dig Dis Sci. 2004; 49:1578-1583.
doi: 10.1023/B:DDAS.0000043367.69470.b7
42. Toshimitsu K, Matsuura B, Ohkubo I, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007; 23: 46-52.
doi: 10.1016/j.nut.2006.09.004
43. Machado MV, Ravasco P, Jesus L, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol. 2008; 43: 95-102. doi: 10.1080/00365520701559003
44. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science. 1987; 237: 885-888. doi: 10.1126/science.3303333
45. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003; 38: 1529-1539. doi: 10.1016/j.hep.2003.09.028
46. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004; 39: 608-616. doi: 10.1002/hep.20093
47. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006; 25: 816-823. doi: 10.1016/j.clnu.2006.01.027
48. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther. 2006; 23: 1143-1151. doi: 10.1111/j.1365-2036.2006.02885.x
49. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves non-lcoholic steatohepatitis. J Clin Gastroenterol. 2008;42: 413-418. doi: 10.1097/MCG.0b013e31815591aa
50. Ibrahim A, Natrajan S, Ghafoorunissa R. Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. Metabolism. 2005; 54: 240-246. Website. http://www.ncbi.nlm.nih.gov/pubmed/15789505. Accessed June 27, 2016
51. Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med. 1997; 337: 1491-1499. doi: 10.1056/NEJM199711203372102
52. Machado RM, Stefano JT, Oliveira CP, et al. Intake of trans fatty acids causes non-alcoholic steatohepatitis and reduces adipose tissue fat content. J Nutr. 2010; 140: 1127-1132. doi: 10.3945/jn.109.117937
53. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-etri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol.2008; 295: G987-G995. doi: 10.1152/ajpgi.90272.2008
54. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: A meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003; 77:1146-1155.
Website. http://ajcn.nutrition.org/content/77/5/1146.full. Accessed June 27, 2016
55. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: A meta-analysis. Am J Clin Nutr. 1998; 67: 577S582.
Website. http://www.ncbi.nlm.nih.gov/pubmed/9497173. Accessed June 27, 2016
56. Hussein O, Grosovski M, Lasri E, Svalb S, Ravid U, Assy N. Monounsaturated fat decreases hepatic lipid content innonalcoholic fatty liver disease in rats. World J Gastroenterol. 2007;13: 361-368. doi: 10.3748/WJG.v13.i3.361
57. Hernandez R, Martinez-Lara E, Canuelo A, et al. Steatosisrecovery after treatment with a balanced sunflower orolive oilbased diet: Involvement of perisinusoidal stellatecells. World J Gastroenterol. 2005; 11: 7480-7485. doi: 10.3748/wjg.v11.i47.7480
58. Szende B, Timar F, Hargitai B. Olive oil decreases liver damage in rats caused by carbon tetrachloride (CCl4). Exp Toxicol Pathol. 1994; 46: 355-359. doi: 10.1016/S0940-2993(11)80116-8
59. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J Hepatol. 2007;47: 711-717. doi: 10.1016/j.jhep.2007.06.020
60. Kainuma M, Fujimoto M, Sekiya N, et al. Cholesterol-fed rabbit as a unique model of non-alcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J Gastroenterol. 2006; 41: 971-980. doi: 10.1007/s00535-006-1883-1
61. Gaby AR. Adverse effects of dietary fructose. Altern Med Rev. 2005; 10: 294-306.
Website. http://www.altmedrev.com/ publications/10/4/294.pdf. Accessed June 27, 2016
62. Brownell KD, Farley T, Willett WC, et al. The public health and economic benefits of taxing sugar-sweetened beverages. N Engl J Med. 2009; 361: 1599-1605. doi: 10.1056/NEJMhpr0905723
63. Duffey KJ, Popkin BM. Shifts in patterns and consumption of beverages between 1965 and 2002. Obesity. 2007; 15: 2739-2747.
doi: 10.1038/oby.2007.326
64. Schulze MB, Manson JE, Ludwig DS, et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004; 292: 927-934. doi: 10.1001/jama.292.8.927
65. Poulsom R. Morphological changes of organs after sucrose or fructose feeding. Prog Biochem Pharmacol. 1986; 21: 104- 134.
Website. http://www.ncbi.nlm.nih.gov/pubmed/3523499. Accessed June 27, 2016
66. Malik VS, Schulze MB, Hu FB. Intake of sugar-sweetened beverages and weight gain: A systematic review. Am J Clin Nutr. 2006; 84: 274-288. Website. http://www.ncbi.nlm.nih.gov/pubmed/16895873. Accessed June 27, 2016
67. Vartanian LR, Schwartz MB, Brownell KD. Effects of soft drink consumption on nutrition and health: A systematic review and meta-analysis. Am J Public Health. 2007; 97: 667-675. doi: 10.2105/AJPH.2005.083782
68. Fung TT, Malik V, Rexrode KM, Manson JE, Willett WC, Hu FB. Sweetened beverage consumption and risk of coronary heart disease in women. Am J Clin Nutr. 2009; 89: 1037-1042. doi: 10.3945/ajcn.2008.27140
69. Malik VS, Popkin BM, Bray GA, Despres JP, Willett WC, Hu FB. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: A meta-analysis. Diabetes Care. 2010; 33: 2477-2483. doi: 10.2337/dc10-1079
70. Herman RH, Zakim D, Stifel FB. Effect of diet on lipid metabolism in experimental animals and man. Fed Proc. 1970; 29: 1302-1307.
Website. http://www.ncbi.nlm.nih.gov/pubmed/4245709. Accessed June 27, 2016
71. Cave M, Deaciuc I, Mendez C, et al. Non-alcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem. 2007; 18: 184-195. doi: 10.1016/j.jnutbio.2006.12.006
72. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008; 48: 993-999.
doi: 10.1016/j.jhep.2008.02.011
73. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009; 51: 918-924. doi: 10.1016/j.jhep.2009.05.033
74. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology. 2010; 51: 1961-1971. doi: 10.1002/hep.23535
75. Hu FB, Rimm EB, Stampfer MJ, Ascherio A, Spiegelman D, Willett WC. Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr. 2000; 72: 912-921. Website. http://www.ncbi.nlm.nih.gov/pubmed/11010931. Accessed June 27, 2016
76. Pereira MA, Kartashov AI, Ebbeling CB, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet. 2005; 365: 36-42. doi: 10.1016/S0140-6736(04)17663-0
77. Kechagias S, Ernersson A, Dahlqvist O, et al. Fast-foodbased hyper- limentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut. 2008; 57: 649-654. doi: 10.1136/gut.2007.131797
78. Marchesini G, Ridolfi V, Nepoti V. Hepatotoxicity of fast food? Gut. 2008; 57: 568-570. doi: 10.1136/gut.2007.143958
79. Rozental P, Biava C, Spencer H, Zimmerman HJ. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis. 1967; 12: 198-208. doi: 10.1007/BF02233443
80. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med. 1970; 282: 829-834. doi: 10.1056/NEJM197004092821502
81. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991; 12: 224-229. Website. http://www.ncbi.nlm.nih. gov/pubmed/2051001. Accessed June 27, 2016
82. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990; 99: 1408-1413. Website. http://www.ncbi.nlm.nih.gov/pubmed/2210247. Accessed June 27, 2016
83. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of estricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997; 27: 103-107. doi: 10.1016/S0168-8278(97)80287-5
84. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol. 2005; 100: 1072-1081. doi: 10.1111/j.1572-0241.2005.41334.x
85. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology. 2010; 51: 121-129. doi: 10.1002/hep.23276
86. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with non-alcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009; 49: 80-86. doi: 10.1002/hep.22575
87. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010; 33: 2156-2163. doi: 10.2337/dc10-0856
88. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in non-alcoholic fatty liver disease. J Hepatol. 2005; 43: 1060-1066. doi: 10.1016/j.jhep.2005.06.008
89. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009; 24: 399-407. doi: 10.1111/j.1440-1746.2008.05694.x
90. Oza N, Eguchi Y, Mizuta T, et al. A pilot trial of body weight reduction for non-alcoholic fatty liver disease with a homebased lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol. 2009;44: 1203-1208.
doi: 10.1007/s00535-009-0115-x
91. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW 3rd, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: A randomized trial. JAMA. 1999; 281: 327-334. doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-4-joc80889
92. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol. 2005; 99: 1193-1204. doi: 10.1152/japplphysiol.00160.2005
93. LaMonte MJ, Blair SN, Church TS. Physical activity and diabetes prevention. J Appl Physiol. 2005; 99: 1205-1213.
doi: 10.1152/japplphysiol.00193.2005
94. Bauman AE. Updating the evidence that physical activity is good for health: An epidemiological review 2000-2003. J SciMed Sport. 20 04; 7: 6-19. Website. http://www.ncbi.nlm.nih.gov/pubmed/15214597. Accessed June 27, 2016
95. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997; 20:537-544. doi: 10.2337/diacare.20.4.537
96. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, et al. Role of leisure-time physical activity in non-alcoholic fatty liver disease: A population-based study. Hepatology. 2008; 48: 1791-1798. doi: 10.1002/hep.22525
97. Church TS, Kuk JL, Ross R, Priest EL, Biltoft E, Blair SN. Association of cardiorespiratory fitness, body mass index, and waist circumference to non-alcoholic fatty liver disease. Gastroenterology. 2006; 130: 2023-2030. doi: 10.1053/j.gastro.2006.03.019
98. Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with non-alcoholic fatty liver disease. Hepatology. 2008; 47: 1158-1166. doi: 10.1002/hep.22137
99. St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with non-alcoholic fatty liver disease. Hepatology. 2009; 50: 68-76. doi: 10.1002/hep.22940
100. Sreenivasa Baba C, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2006; 21: 191-198. doi: 10.1111/j.1440-1746.2005.04233.x
101. Johnson NA, Sachinwalla T, Walton DW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology. 2009; 50: 1105-1112. doi: 10.1002/hep.23129
102. Kantartzis K, Thamer C, Peter A, et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut. 2009; 58: 1281-1288. doi: 10.1136/gut.2008.151977
103. Van Der Heijden GJ, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc. 2010; 42: 1973-1980. doi: 10.1249/MSS.0b013e3181df16d9
104. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. JAMA. 2001; 286: 1218-1227. doi: 10.1001/jama.286.10.1218
105. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med. 1998; 49: 235-261.
doi: 10.1146/annurev.med.49.1.235
106. Hannukainen JC, Nuutila P, Borra R, et al. Increased physical activity decreases hepatic free fatty acid uptake: A study in human monozygotic twins. J Physiol. 2007; 578: 347-358. doi: 10.1113/jphysiol.2006.121368
107. Tamura Y, Tanaka Y, Sato F, et al. Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2005; 90: 3191-3196. doi: 10.1210/jc.2004-1959#sthash.hkbBx0DQ.dpuf
108. Iozzo P, Takala T, Oikonen V, et al. Effect of training status on regional disposal of circulating free fatty acids in the liver and skeletal muscle during physiological hyperinsulinemia. Diabetes Care. 2004; 27: 2172-2177. doi: 10.2337/diacare.27.9.2172
109. Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: Exercise and type 2 diabetes. Med Sci Sports Exerc. 2000; 32: 1345-1360. Website. http://www.ncbi.nlm.nih.gov/pubmed/10912903. Accessed June 27,2016
110. Pollock ML, Franklin BA, Balady GJ, et al. Resistance exercise in individuals with and without cardiovascular disease. Benefits, rationale, safety, and prescription: An advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, American heart association; position paper endorsed by the American College of Sports Medicine. Circulation. 2000; 101: 828-833. doi: 10.1161/01.CIR.101.7.828
111. Ibanez J, Izquierdo M, Arguelles I, et al. Twice-weekly progressive resistance training decreases abdominal fat and improves insulin sensitivity in older men with type 2 diabetes. Diabetes Care. 2005; 28: 662-667. doi: 10.2337/diacare.28.3.662
112. Tsuzuku S, Kajioka T, Endo H, Abbott RD, Curb JD, Yano K. Favorable effects of non-instrumental resistance training on fat distribution and metabolic profiles in healthy elderly people. Eur J Appl Physiol. 2007; 99: 549-555. doi: 10.1007/s00421-006-0377-4
113. Banz WJ, Maher MA, Thompson WG, et al. Effects of resistance versus aerobic training on coronary artery disease risk factors. Exp Biol Med. 2003; 228: 434-440. Website. http://ebm.sagepub.com/content/228/4/434.long. Accessed June 27, 2016
114. Ballor DL, Keesey RE. A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass and fat-free mass in males and females. Int J Obes. 1991; 15: 717-726. Website. http://www.ncbi.nlm.nih.gov/pubmed/1838100. Accessed June 27, 2016
115. Miller WJ, Sherman WM, Ivy JL. Effect of strength training on glucose tolerance and post-glucose insulin response. Med Sci Sports Exerc. 1984; 16: 539-543. Website. http://www.ncbi. nlm.nih.gov/pubmed/6392812. Accessed June 27, 2016
116. Pratt M, Macera CA, Blanton C. Levels of physical activity and inactivity in children and adults in the United States: Current evidence and research issues. Med Sci Sports Exerc. 1999; 31: S526-S533. Website. http://www.ncbi.nlm.nih.gov/pubmed/10593523. Accessed June 27, 2016
117. Peterson JA. Get moving! Physical activity counseling in primary care. J Am Acad Nurse Pract. 2007; 19: 349-357.
doi: 10.1111/j.1745-7599.2007.00239.x
118. Morrato EH, Hill JO, Wyatt HR, Ghushchyan V, Sullivan PW. Physical activity in U.S. adults with diabetes and at risk for developing diabetes, 2003. Diabetes Care. 2007; 30: 203-209. doi: 10.2337/dc06-1128
119. Zhao G, Ford ES, Li C, Mokdad AH. Compliance with physical activity recommendations in US adults with diabetes. Diabet Med. 2008; 25: 221-227. doi: 10.1111/j.1464-5491.2007.02332.x
120. Newton JL, Jones DE, Henderson E, et al. Fatigue in nonalcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008; 57:807-813. doi: 10.1136/gut.2007.139303
121. Helmerhorst HJ, Wijndaele K, Brage S, Wareham NJ, Ekelund U. Objectively measured sedentary time may predict insulin resistance independent of moderate- and vigorous-intensity physical activity. Diabetes. 2009; 58: 1776-1779. doi: 10.2337/db08-1773
122. American Heart Association Nutrition Committee, Lichtenstein AH, Appel LJ, et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006; 114: 82-96.
doi: 10.1161/CIRCULATIONAHA.106.176158
123. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: A pilot study. Aliment Pharmacol Ther. 2001; 15: 1667-1672. doi: 10.1046/j.1365-2036.2001.01083.x
124. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003; 38: 413-419. doi: 10.1053/jhep.2003.50316
125. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol. 2003; 98: 2485-2490. doi: 10.1111/j.1572-0241.2003.08699.x
126. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for non-alcoholic steatohepatitis. N Engl J Med. 2010; 362: 1675-1685. doi: 10.1056/NEJMoa0907929
127. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The physicians’ health study II randomized controlled trial. JAMA. 2008; 300: 2123-2133. doi: 10.1001/jama.2008.600
128. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; CD007176. doi: 10.1002/14651858. CD007176.pub2
129. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007; 92: 2017-2029. doi: 10.1210/jc.2007-0298#sthash.zVEDzof1.dpuf
130. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. Atherosclerosis. 2009; 205: 255-260. doi: 10.1016/j.atherosclerosis.2008.10.033
131. Pittas AG, Chung M, Trikalinos T, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010; 152: 307-314.
doi: 10.7326/0003-4819-152-5-201003020-00009
132. Kayaniyil S, Vieth R, Retnakaran R, et al. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010; 33:1379-1381. doi: 10.2337/dc09-2321
133. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2007; 17: 517-524. doi: 10.1016/j.numecd.2006.04.002
134. Nseir WMA, Abu Mouch S, Grosovski M, Assy N. Association between 25-OH vitamin D concentrations and risk of coronary artery disease in patients with non alcoholic fatty liver disease. Hepatology. 2010; 52(Suppl 1).
135. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51: 1889-1895. doi: 10.2337/diabetes.51.6.1889
136. Hanley AJ, Williams K, Festa A, et al. Insulin resistance atherosclerosis study. Elevations in markers of liver injury and risk of type 2 diabetes: The insulin resistance atherosclerosis study. Diabetes. 2004; 53: 2623-2632. doi: 10.2337/diabetes.53.10.2623
137. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care. 2005; 28: 2913-2918. doi: 10.2337/diacare.28.12.2913
138. Marchesini G, Forlani G. NASH: From liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002; 35: 497-499.
doi: 10.1053/jhep.2002.31551
139. Fracanzani AL, Burdick L, Rasselli S, et al. Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with NAFLD: A case control study. J Hepatol. 2006; 44: S39.
140. Ekstedt M, Fran’zen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Survival and causes of death in patients with elevated liver enzymes associated with NAFLD. J Hepatol. 2006; 44: S40. doi: 10.1002/hep.21327
141. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in non-alcoholic fatty liver disease. Hepatology. 2005; 42: 473-480. doi: 10.1002/hep.20781
142. Targher G, Bertolini L, Poli F, et al. Non-alcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54: 3541-3546. doi: 10.2337/ diabetes.54.12.3541
143. Jepsen P, Vilstrup H, Mellemkjaer L, et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology. 2003; 50: 2101-2104. Website. http://www.ncbi.nlm.nih.gov/pubmed/14696473. Accessed June 27, 2016
144. Kessler A, Levy Y, Roth A, et al. Increased prevalence of NAFLD in patients with acute myocardial infarction independent of BMI. Hepatology. 2005; 42(Suppl 1): A623.
145. Bogin E, Avidar Y, Merom M. Biochemical changes in liver and blood during liver fattening in rats. J Clin Chem Clin Biochem. 1986; 24: 621-626.Website. http://edoc.hu-berlin.de/oa/ degruyter/cclm.1986.24.9.621.pdf. Accessed June 27, 2016
146. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53: 372-384. doi: 10.1016/j.jhep.2010.04.008
147. Fabricatore AN. Behavior therapy and cognitive-behavioral therapy of obesity: Is there a difference? J Am Diet Assoc. 2007; 107: 92-99.
doi: 10.1016/j.jada.2006.10.005
148. Anderson AS. How to implement dietary changes to prevent the development of metabolic syndrome. Br J Nutr. 2000; 83(Suppl 1): S165-S168. doi: 10.1017/S0007114500001112
149. Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med. 2001; 161: 218-227. doi: 10.1001/archinte.161.2.218
150. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008; 93: S74-S80.
doi: 10.1210/jc.2008-1399
151. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Fatty Liver Italian Network. Behavior therapy for non-alcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008; 47: 746-754. doi: 10.1002/hep.22009